Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer

This study has been completed.
Eli Lilly and Company
Information provided by:
Herlev Hospital Identifier:
First received: June 23, 2005
Last updated: October 1, 2007
Last verified: October 2007
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2007
  Estimated Primary Completion Date: No date given